Acter (5536) Q2 2025 earnings summary

Executive summary

• Achieved record-high consolidated revenue of NT$19.46 billion and EPS of NT$12.13 for 2025H1, with a backlog exceeding NT$47 billion, supporting future operations.

• Net income attributable to owners for the six months was NT$1,504.7 million, compared to NT$1,244.7 million in the prior year period.

• Operations span 10 countries, with a diversified client base and broad industry coverage, including semiconductors, electronics, and healthcare.

• The review report was qualified due to certain subsidiaries' financials not being reviewed by independent auditors, representing 15% of assets and 14% of liabilities.

Financial highlights

• 2025H1 operating revenue rose to NT$19.46 billion from NT$13.14 billion in 2024H1, a 48% increase year-over-year.

• 2025H1 EPS reached NT$12.13 (par value NT$5), up from NT$10.03 in 2024H1.

• Gross profit margin was 19% in 2025H1, with operating income at NT$2.59 billion.

• Cash and cash equivalents at end of June 2025 were NT$10.72 billion, with positive operating cash flow of NT$2.5 billion for 2025H1.

• Total assets increased to NT$37.18 billion, and total liabilities rose to NT$21.04 billion as of June 2025.

Outlook and guidance

• High backlog of over NT$47 billion ensures robust future revenue streams.

• Cleanroom and semiconductor markets expected to grow, with global cleanroom technology market projected to reach USD 7.85 billion by 2034.

• Focus on leveraging AI, regionalization, and net-zero carbon opportunities to drive future growth.

• Adoption of new IFRS standards is not expected to have a significant impact; IFRS 18 impact is being evaluated.